Topical treatment of vitiligo by a JAK inhibitor
US11602536B2 · kind B2 · utility
1Cited by
12References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2020 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | May 5, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.